J Cummings1, M Ranson, F Butt, D Moore, C Dive. 1. Clinical and Experimental Pharmacology Group, Paterson Institute for Cancer Research, University of Manchester, Wilmslow Road, Manchester, M20 4BX, England. jcummings@picr.man.ac.uk
Abstract
PURPOSE: M30 and M65 ELISAs are proposed as surrogate biomarkers of tumour cell death in patients and are being applied increasingly in the pharmacodynamic (PD) evaluation of anticancer drugs during clinical trials. In the absence of such data, we have studied the long-term stability of the antigens of both assays in plasma of cancer patients stored at -80 degrees C over 2 years. RESULTS: No evidence was detected of degradation in the M65 antigen. However, in a proportion of patients significant increases in levels of M30 antigen were detected CONCLUSION: Plasma samples for M65 analysis can be stored at -80 degrees C for 2 years; however, caution is recommended when considering long-term storage of samples for the M30 assay.
PURPOSE: M30 and M65 ELISAs are proposed as surrogate biomarkers of tumour cell death in patients and are being applied increasingly in the pharmacodynamic (PD) evaluation of anticancer drugs during clinical trials. In the absence of such data, we have studied the long-term stability of the antigens of both assays in plasma of cancerpatients stored at -80 degrees C over 2 years. RESULTS: No evidence was detected of degradation in the M65 antigen. However, in a proportion of patients significant increases in levels of M30 antigen were detected CONCLUSION: Plasma samples for M65 analysis can be stored at -80 degrees C for 2 years; however, caution is recommended when considering long-term storage of samples for the M30 assay.
Authors: Daniel J Antoine; Rosalind E Jenkins; James W Dear; Dominic P Williams; Mitchell R McGill; Matthew R Sharpe; Darren G Craig; Kenneth J Simpson; Hartmut Jaeschke; B Kevin Park Journal: J Hepatol Date: 2012-01-17 Impact factor: 25.083
Authors: Esther C de Haas; Alessandra di Pietro; Kathryn L Simpson; Coby Meijer; Albert J H Suurmeijer; Lee J Lancashire; J Cummings; Steven de Jong; Elisabeth G E de Vries; Caroline Dive; Jourik A Gietema Journal: Neoplasia Date: 2008-10 Impact factor: 5.715
Authors: C Dive; R A Smith; E Garner; T Ward; S St George-Smith; F Campbell; W Greenhalf; P Ghaneh; J P Neoptolemos Journal: Br J Cancer Date: 2010-01-05 Impact factor: 7.640